This article is more than 5 years old. Information may no longer be current.

EyePoint posts $7 million quarterly loss

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyePoint Pharmaceuticals, formerly pSivida, reported a net loss of $7 million, or $0.15 per share, in its third fiscal quarter compared with a net loss of $5.1 million, or $0.15 per share, in the same quarter of 2017.

Revenue for the quarter was $928,000 compared with $590,000 a year ago, according to a press release.

Quarterly operating expenses decreased from $5.8 million in 2017 to $5.6 million in 2018.

The company had cash and cash equivalents of $16.3 million as of March 31.